Hanx Biopharmaceuticals Achieves Major R&D Milestones with Four Posters at 2026 AACR Annual Meeting

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (Stock Code: 3378) announced a significant milestone in its ongoing research and development activities, unveiling four innovative drug research poster presentations at the prestigious 2026 Annual Meeting of the American Association for Cancer Research (AACR) held at the San Diego Convention Center, California, USA, from April 17 to 22, 2026.

Key Highlights from the AACR 2026 Meeting

• Four Innovative Drug Abstracts Showcased: The company’s advancements highlight its robust R&D capabilities and growing innovation strength, with each poster presenting potentially market-moving data on novel therapies targeting major unmet needs in solid tumor treatments.
• Pipeline Advances in Next-Generation Immunotherapy: The research presented includes globally innovative fusion proteins and antibody-drug conjugates (ADCs), positioning Hanx Biopharmaceuticals as a potential leader in the oncology sector.

Details of Poster Presentations

1. CTLA-4/SIRPα Bifunctional Fusion Protein: HX044

• Innovation: HX044 is a first-in-class, next-generation bifunctional fusion protein targeting CTLA-4 and SIRPα (CD47), designed for solid tumors with resistance to PD-1/ICI therapy.
• Mechanism: By simultaneously targeting CTLA-4 and CD47, HX044 enhances regulatory T-cell depletion within the tumor microenvironment, reducing immunosuppression and boosting anti-tumor immunity.
• Preclinical Data:
  • Preferential targeting of tumor-infiltrating regulatory T-cells (TIL-Treg) demonstrated, which express higher levels of CTLA4.
  • Widened therapeutic window compared to ipilimumab, with about 4x improved efficacy at lower doses and minimal increase in immune-related adverse events.
  • Currently in Phase I clinical development, laying a solid foundation for future clinical trials and potential commercialization.
• Potential Impact: Breakthrough in treating solid tumors resistant to existing immunotherapies, possibly leading to higher market share and valuation upon successful clinical results.

2. Bispecific Antibody-Drug Conjugate (BsAb ADC): HX116

• Innovation: HX116 is a potential first-in-class bispecific ADC targeting both PD-L1 and VEGF, developed in-house by Hanx Biopharmaceuticals.
• Mechanism & Activity:
  • Combines direct tumor-cell killing with enhanced anti-tumor immunity via immunogenic cell death.
  • Demonstrated superior anti-tumor activity over parental BsAb in preclinical models.
  • Efficient internalization in PD-L1+ cells, especially in the presence of VEGF, suggesting enhanced efficacy in tumors with high VEGF expression.
  • Comparable cytotoxicity to SGN-PDL1V (the current clinical lead), with indications of more specific tumor targeting and potentially reduced off-tumor toxicity.
• Potential Impact: Could establish Hanx as a key player in the ADC field if clinical efficacy is confirmed, with significant market potential.

3. PD-L1 Targeted Antibody-Drug Conjugate: HX112

• Innovation: HX112 is a novel ADC designed for pan-solid tumors, showing efficient internalization and cytotoxicity in 3D tumor organoid models—more reflective of real tumor biology.
• Key Findings:
  • Demonstrated similar or superior tumor specificity compared to SGN-PDL1V in 3D organoids.
  • Potential to avoid the use of tumor microenvironment (TME)-cleavable linkers, which could reduce off-target toxicity and side effects.
• Potential Impact: May offer a safer and more effective treatment option for a broad range of solid tumors, enhancing the company’s competitive advantage.

4. 3D Tumor Organoid ADC Evaluation System

• Innovation: Hanx Biopharmaceuticals has developed a new preclinical evaluation platform using 3D tumor organoids, which more accurately predict in vivo anti-tumor efficacy compared to traditional 2D cell cultures.
• Key Findings:
  • Significant differences in internalization and cytotoxicity of ADCs, depending on the antibody epitope, were observed in 3D versus 2D systems.
  • 3D organoids are more predictive of clinical outcomes, supporting a streamlined and more effective preclinical candidate assessment process.
• Potential Impact: This innovation enhances drug development efficiency and could accelerate the path to market for Hanx’s pipeline candidates.

Strategic and Shareholder Considerations

• R&D Validation: The positive data from multiple programs underscore Hanx’s R&D strength and commitment to next-generation immunotherapies for cancer and autoimmune diseases.
• Clinical Pipeline Progress: HX044’s advancement into Phase I and promising preclinical results for HX116 and HX112 could lead to significant value inflection points as data matures.
• Market Differentiation: First-in-class and best-in-class claims, if substantiated in the clinic, could position Hanx as a leader in the highly competitive oncology market.
• Commercial Potential: Each program targets large, underserved markets in solid tumor oncology, offering considerable revenue upside if successfully commercialized.
• Risk Warning: The company specifically warns that these products are still under development and may not ultimately be successfully marketed. Shareholders and potential investors should exercise caution, as clinical trial setbacks or failures could negatively impact share value.

About Hanx Biopharmaceuticals

Founded in 2014, Hanx Biopharmaceuticals is an innovative biotech company focused on structural biology, translational medicine, and clinical development, aiming to deliver affordable, safe, and effective therapies for cancer and autoimmune diseases globally.

Board and Leadership

The board is led by Dr. Zhang Faming (Chairman and Executive Director), with a team comprising experienced executives and independent directors, ensuring strong governance and strategic direction.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. The products and clinical programs described are in various stages of development and may not ultimately achieve regulatory approval or commercial success. Shareholders and potential investors should be aware of the risks and exercise caution when dealing with shares of Hanx Biopharmaceuticals (Wuhan) Co., Ltd.

View HANXBIO-B Historical chart here